2019
A Proposed Grading Scale for Predicting Outcomes After Stereotactic Radiosurgery for Dural Arteriovenous Fistulas
Mohammed N, Hung YC, Chen CJ, Xu Z, Schlesinger D, Kano H, Chiang V, Hess J, Lee J, Mathieu D, Kaufmann AM, Grills IS, Cifarelli CP, Vargo JA, Chytka T, Janouskova L, Feliciano CE, Mercado RR, Lunsford LD, Sheehan JP. A Proposed Grading Scale for Predicting Outcomes After Stereotactic Radiosurgery for Dural Arteriovenous Fistulas. Neurosurgery 2019, 87: 247-255. PMID: 31584074, PMCID: PMC7528658, DOI: 10.1093/neuros/nyz401.Peer-Reviewed Original ResearchConceptsDural arteriovenous fistulaCranial dural arteriovenous fistulasCortical venous refluxFavorable outcomeStereotactic radiosurgeryGrading systemIntracerebral hemorrhageArteriovenous fistulaScoring systemGrading scaleKaplan-Meier analysisPrior intracerebral hemorrhageClass II patientsLogistic regression analysisPractical grading systemDAVF obliterationVenous refluxII patientsClinical parametersSinus locationPredicting OutcomeSystematic reviewClass IIIPatientsROC analysisSurvival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?
Sperduto PW, Fang P, Li J, Breen W, Brown PD, Cagney D, Aizer A, Yu J, Chiang V, Jain S, Gaspar LE, Myrehaug S, Sahgal A, Braunstein S, Sneed P, Cameron B, Attia A, Molitoris J, Wu CC, Wang TJC, Lockney N, Beal K, Parkhurst J, Buatti JM, Shanley R, Lou E, Tandberg DD, Kirkpatrick JP, Shi D, Shih HA, Chuong M, Saito H, Aoyama H, Masucci L, Roberge D, Mehta MP. Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress? Translational Research 2019, 208: 63-72. PMID: 30885538, PMCID: PMC6527460, DOI: 10.1016/j.trsl.2019.02.011.Peer-Reviewed Original ResearchConceptsGI cancer patientsBrain metastasesGraded Prognostic AssessmentCancer patientsPrognostic factorsNew brain metastasesLarge contemporary cohortPrognosis of patientsLog-rank testMedian survival estimatesContemporary cohortPrognostic indexClinical parametersGastrointestinal cancerPrimary diagnosisPrognostic assessmentRetrospective IRBPatientsFirst treatmentDemographic dataSurvival estimatesCurrent cohortCohortTreatmentPrognosis
2018
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases
Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2018, 101: 845-853. PMID: 29976497, PMCID: PMC6925530, DOI: 10.1016/j.ijrobp.2018.04.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic AgentsBrain NeoplasmsCarcinoma, Renal CellCause of DeathCranial IrradiationCytokinesFemaleHemoglobinsHumansImmunotherapyKarnofsky Performance StatusKidney NeoplasmsMaleMiddle AgedMultivariate AnalysisPrognosisRadiosurgeryRetrospective StudiesYoung AdultConceptsPatterns of careNew brain metastasesBrain metastasesLarge contemporary cohortPrognostic factorsMedian survivalContemporary cohortRCC patientsDiagnosis of BMWhole-brain radiation therapyRenal cell carcinoma patientsRetrospective institutional review boardBrain metastasis therapySystemic treatment optionsAdditional prognostic factorsCell carcinoma patientsRenal cell carcinomaInstitutional review boardNonneurologic causesCarcinoma patientsImproved survivalNeurologic causesMultivariable analysisClinical parametersPresent cohort
2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 1069-1077. PMID: 28721890, PMCID: PMC6925531, DOI: 10.1016/j.ijrobp.2017.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsFemaleGenes, rasHumansImmunotherapyLinear ModelsMaleMelanomaMiddle AgedMolecular Targeted TherapyMutationPrognosisProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitRetrospective StudiesStatistics, NonparametricTime FactorsConceptsBRAF-negative patientsBRAF-positive patientsBrain metastasesMedian survivalC-kit mutationsMelanoma patientsPrimary diagnosisWhole-brain radiation therapyOverall median survivalMulti-institutional databaseGene mutation statusOverall survivalInitial treatmentMedian timeTreatment patternsClinical parametersBRAF statusPrognostic valueNRAS mutationsRadiation therapyPatientsMutation statusMetastasisC-kitMEK inhibitors